Beam Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Beam Therapeutics reported positive Phase 1/2 clinical data for its sickle cell disease candidate, risto-cel, and secured a $500 million credit facility, while continuing to advance its broad gene editing pipeline.
NASDAQ
10-K: Beam Therapeutics Reports Progress in Gene Editing Platform, Anticipates Key Clinical Data in 2025
Beam Therapeutics advances its precision genetic medicine platform, expecting initial clinical data for BEAM-302 and BEAM-301 in the first half of 2025 and dosing 30 patients in the BEACON trial by mid-2025.
NASDAQ
Beam Therapeutics has amended its lease agreement for its Durham, North Carolina facility, finalizing the base rent and addressing other terms.